| P/E (FY) | — | Sales (TTM) | SEK 261.9M |
| Earnings (TTM) | -SEK 29.8M | ROE | −8.75% |
| Net Margin | −11.39% | ROIC | −5.76% |
| Debt / Equity | 0.52 | TD / EBITDA | 9.48 |
| EPS Growth 3Y | — | Sales Growth 3Y | 13.51% |
Bactiguard Holding AB is a medtech company providing infection-prevention technology and solutions across areas such as orthopedics, cardiology, neurology, urology, and vascular access. It also markets wound-management products, including the Hydrocyn Aqua antimicrobial solution and gel, and a range of surgical sutures. Bactiguard licenses its technology to global medtech companies that incorporate it into their own and co-branded medical devices, with partners including Becton Dickinson, Well Lead Medical, and Zimmer Biomet. The company operates internationally, including in the United States, Sweden, Malaysia, India, and Saudi Arabia; it was founded in 2005 and is headquartered in Stockholm, Sweden.
| Market Cap | $57.1M | Trading Days | 2991 |
| 52W High | 34.70 |
| 52W Low | 13.60 |
| % Off High | −54.32% |
| YTD | −20.35% | 1Y | −47.17% |
| 3Y | −78.29% | 5Y | −91.28% |
| 10Y | 14.86% | Since incept. (ann.) | −5.52% |
| Ann. Volatility (1Y) | 71.30% | Ann. Volatility (3Y) | 64.28% |
| Sharpe (1Y) | −0.58 | Sharpe (3Y) | −0.54 |
| Max Drawdown (1Y) | −57.49% | Max Drawdown (3Y) | −84.29% |
| Beta (3Y, vs SPY) | 0.50 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SCLX | Scilex Holding Co | $57.9M | — |
| ELTX | Elicio Therapeutics, Inc. | $56.3M | — |
| CRDF | Cardiff Oncology, Inc. | $55.9M | — |
| ANVS | Annovis Bio, Inc. | $58.6M | — |
| PMVP | PMV Pharmaceuticals, Inc. | $58.7M | — |
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| XSPRAY.ST | Xspray Pharma AB (publ) | $55.3M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| DRIO | DarioHealth Corp. | $54.8M | 0.7 |
| SNWV | SANUWAVE Health, Inc. | $54.7M | 4.6 |
| XTNT | Xtant Medical Holdings, Inc. | $59.7M |
| 14.2 |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
